Progesterone News and Research RSS Feed - Progesterone News and Research

Researchers reveal direct link between Wbp2 gene and progressive hearing loss

Researchers reveal direct link between Wbp2 gene and progressive hearing loss

Researchers at King's College London and the Wellcome Trust Sanger Institute in the United Kingdom have for the first time demonstrated a direct link between the Wbp2 gene and progressive hearing loss. The scientists report that the loss of Wbp2 expression leads to progressive high-frequency hearing loss in mouse as well as in two clinical cases of children with deafness with no other obvious features. [More]
Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

While there are a range of reports that different foods and food groups can increase or decrease your risk of cancer, these associations are very difficult to scientifically verify. [More]
Migraines heat up as women near menopause

Migraines heat up as women near menopause

Migraine headaches heat up as women approach menopause, according to a new study from researchers at the University of Cincinnati, Montefiore Headache Center, Albert Einstein College of Medicine and Vedanta Research. [More]
Study findings may help explain why risk of stroke changes after menopause

Study findings may help explain why risk of stroke changes after menopause

Risk of stroke in women may come down to a compound the body produces from estrogen known as 2-methoxyestradiol (2-ME). Furthermore, the compound's therapeutic potential may extend beyond treating stroke in women to healing brain injuries in men, a new study in American Journal of Physiology—Endocrinology and Metabolism reports. [More]
Racial disparity in 'previable' preterm births linked to infant mortality problem

Racial disparity in 'previable' preterm births linked to infant mortality problem

Black women are nearly four times more likely than white women to have a baby born between 16 and 22 weeks gestation, a time period in which the life of a baby outside the womb is not viable. [More]
Biocept introduces blood-based test for detection, monitoring of prostate cancer and breast cancer

Biocept introduces blood-based test for detection, monitoring of prostate cancer and breast cancer

Biocept, Inc., a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient's blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer. [More]
TSRI-led study finds potential new therapeutic approach for hard-to-treat breast cancers

TSRI-led study finds potential new therapeutic approach for hard-to-treat breast cancers

Findings from a new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) suggest a potent new therapeutic approach for a number of hard-to-treat breast cancers. [More]
Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III DBCG77B clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. [More]
Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium. [More]
Phase II study hints at oestriol effect in multiple sclerosis

Phase II study hints at oestriol effect in multiple sclerosis

Oestriol, given in combination with glatiramer acetate, may reduce the risk of relapse in women with relapsing–remitting multiple sclerosis, suggest findings from a phase II trial. [More]
Progesterone supplements fail to improve birth rate among women with a history of miscarriage

Progesterone supplements fail to improve birth rate among women with a history of miscarriage

A new study has shown that taking progesterone supplements during the first trimester of pregnancy does not improve the chances of maintaining pregnancy among women who have a history of unexplained recurrent miscarriage. [More]
Uninsured, low-income breast cancer patients less likely to continue hormonal therapy

Uninsured, low-income breast cancer patients less likely to continue hormonal therapy

A University of Colorado Cancer Center study published in the journal Breast Cancer Research and Treatment shows that breast cancer patients whose health insurance plans included prescription drug benefits were 10 percent more likely to start important hormonal therapy than patients who did not have prescription drug coverage. [More]

Juniper Pharmaceuticals’ third quarter product revenues increase 22% to $7.2 million

Juniper Pharmaceuticals, Inc., a women's health therapeutics company, today announced financial results for the three months ended September 30, 2015. [More]
City of Hope awarded NIH grant to study potential link between environmental factors and breast cancer

City of Hope awarded NIH grant to study potential link between environmental factors and breast cancer

The National Institutes of Health has awarded City of Hope a five-year, $4.8 million grant to study the possible role of chemicals in the environment in the development of breast cancer during the menopausal transition in women. [More]
March of Dimes Premature Birth Report Card reveals racial, ethnic disparities within states

March of Dimes Premature Birth Report Card reveals racial, ethnic disparities within states

Portland, Oregon has the best preterm birth rate of the top 100 cities with the most births nationwide, while Shreveport, Louisiana has the worst, according to the 2015 March of Dimes Premature Birth Report Card, which for the first time graded cities and counties around the nation and revealed persistent racial, ethnic and geographic disparities within states. [More]
Breastfeeding associated with lower risk of developing hormone-receptor negative breast cancer

Breastfeeding associated with lower risk of developing hormone-receptor negative breast cancer

A large international study shows that breastfeeding is associated with a lower risk of developing an aggressive form of breast cancer called hormone-receptor negative. This new combined evidence shows the risk was reduced by up to 20% in women who breastfed. [More]
Research provides novel insight into potential new therapeutic targets for triple-negative breast cancer

Research provides novel insight into potential new therapeutic targets for triple-negative breast cancer

Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult to treat and aggressive form of the disease. [More]
Minority women with subtypes of breast cancer less likely to receive recommended treatment regimens

Minority women with subtypes of breast cancer less likely to receive recommended treatment regimens

Main Finding(s): Minority women were more likely to have aggressive subtypes of breast cancer and were more likely to receive non-guideline concordant treatment when compared with non-Hispanic white women. [More]
FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg. [More]
Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on identifying women who are candidates for treatment of menopausal symptoms and selecting the best treatment options for each individual. [More]
Advertisement
Advertisement